Company / Financials
AVENUE THERAPEUTICS, INC. Financials
FY2025-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$1.4M
FY2025 · NaN% YoY
Net Income
-$2.9M
FY2025 · NaN% YoY
Profit Margin
-207.2%
FY2025 · net income / revenue
ROE
-158.8%
FY2025 · return on equity
Total Assets
$2.9M
FY2025
Total Debt
-
FY2025
Equity
$1.8M
FY2025
ROA
-99.3%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -32.57 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 1/9 criteria passed
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$1.4MNet Income HistoryProfit after all expenses and taxes-$2.9MOperating Income HistoryProfit from core business operations before interest and taxes-$3.1MSG&A Expense HistorySelling, general, and administrative expenses$3.7MR&D Expense HistoryResearch and development spending$1.0MIncome Tax HistoryTotal income tax expense$2.0KEPS (Basic) HistoryBasic earnings per share-$15.79Shares Outstanding HistoryWeighted average diluted shares outstanding2.1MTotal Assets HistoryTotal value of all assets owned$2.9MShareholders' Equity HistoryTotal assets minus total liabilities$1.8M